Indolent Lymphoma – Research into a Tailored Treatment Pathway
Meet Dr Josh Tobin, Lymphoma Researcher and inaugural Snowdome Foundation Haematology Fellow.
Dr Tobin has a special interest in indolent lymphoma, a type of slow growing non-Hodgkin’s lymphoma. Although incurable, many of those diagnosed will not require treatment but for those who do, some will relapse and experience aggressive disease.
The goal of Dr Tobin’s research is to identify, at diagnosis, patients who are likely to relapse and then offer more tailored treatments from the start. His focus centres around immunotherapy, treatment that uses the body’s own immune system against cancer, ultimately lessening reliance on chemotherapy.
Immunotherapy is described as one of the most exciting breakthroughs in cancer treatment and offers enormous hope for the cancer community.
Dr Tobin was awarded a prestigious American Society of Hematology Global Research Award, which gave him the extraordinary opportunity to spend six months at the MD Anderson Cancer Center based in Houston, Texas to further this research in follicular lymphoma. The MD Anderson Cancer Center is a world leader in cancer care and research.
In addition, Dr Tobin has been offered a prestigious invited speaker position at the American Society of Hematology Annual Conference in 2023 (the largest haematology conference globally).